Financial intelligence for Asia's healthcare markets
Remember me:

Analysis: Private equity flocks to healthcare

Amid questions about the direction of the global economy, investors doubled down on healthcare as a safe haven in 2016, driving up both the number and the value of deals, according to Bain & Company’s sixth Global Healthcare Private Equity and Corporate M&A Report.

Yet, with so much interest in overall healthcare assets, they faced intense competition for deals. This heated struggle bid up valuations and forced healthcare investors to get creative. Many funds took advantage of a disparity between public and private valuations for some healthcare assets, which prompted a surge in public-to-private transactions. The flip side of this trend was a falloff in the number of IPOs, amid a modest decline in overall exit activity.

In sharp contrast to the broader decline in PE deal-making, healthcare PE activity soared globally with disclosed deal values reaching US$36.4 billion in 2016, its highest level since 2007. That marked a nearly 60% increase from the total of US$23.1 billion in 2015. In Asia Pacific, activity was also strong, especially in the provider sector where deal count nearly tripled and there were a total of 52 buyouts, a return to levels last seen in 2013.

“As a long-term bet, healthcare is hard to beat,” said Kara Murphy, a partner in Bain’s Global Healthcare and Private Equity Practices and co-author of the report. “Deal activity will continue to be high as more funds look to deploy capital into the sector. Given the intense competition, funds will need to be increasingly creative to get deals done.”

After three consecutive record-setting years, total deal value in the Asia Pacific region declined somewhat in 2016, to US$3.2 billion from US$4.9 billion in 2015. The falloff was largely due to the lack of a megadeal such as the US$3.3 billion buyout of publicly traded WuXi PharmaTech that dominated 2015. The few mega scale assets that became available in 2016 went to corporate buyers. That said, underlying momentum was strong, with 10 buyouts last year valued at more than US$100 million and an additional US$700 million of the region’s capital was deployed in private investments in public equities.

PE investors continue to find Asia-Pacific’s demographics promising supported by both a growing and aging population, an expanding middle-class and rising burden of both chronic and communicable diseases. This resurgence in deal activity across the region was led by the provider sector, with 31 provider deals in 2016, about three times the number in 2015.

“Healthcare is becoming a go to destination for financial investors in Asia Pacific” said Vikram Kapur, Bain partner and leader of the firms APAC Healthcare practice. “The attractive fundamentals of the sector are bolstered by the fact that, today, assets in the region are reaching the scale that gets more and more PE investors to take notice.”

So what should we expect this year?

“Investors can expect more volatility in 2017,” said Nirad Jain, a partner in Bain’s Global Healthcare and Private Equity Practices and the report’s co-author. “As the turmoil continues, so too will the attractiveness of healthcare as a safe-haven investment. With an aging and ailing global population, demand for healthcare services will rise regardless of whether there are economic headwinds, tailwinds or crosswinds. But, that’s not to say all healthcare investors will have smooth sailing – sky-high valuations for healthcare assets mean that there are choppy waters to navigate.”

In this environment, deal makers will need to continue to be creative and look harder to find targets that have the capacity to deliver meaningful returns.

“In Asia Pacific, the coming of age of assets and growing competition from PE and corporates will continue to raise the bar for investors and they will need to think hard about the differential value add they can bring to targets beyond growth capital” added Kapur.

Posted on: 20/04/2017 UTC+08:00


China Cord Blood Corporation (CCBC), the country’s largest provider of cord blood storage and ancillary services, has reported a 38.7% rise in profits for the full year to 31 March of Rmb126.2 million (US$18.3 million). At the same time, revenues were up 14.6% to Rmb760 million.
Beijing-based Baheal Pharmaceutical Group plans to bring IBM Watson Health’s Watson for Genomics to clinicians across China. The new multi-year agreement comes less than three months after Baheal and IBM launched a strategic alliance to distribute Watson for Oncology in China. The plan is to establish an ecosystem within China to sell the molecular data interpretation technology to clinicians and researchers across the country. Financial terms have not been disclosed.
Medical insurance provider ALC Health has been confirmed as a Lloyd's Coverholder in Hong Kong. ALC Health, a subsidiary of global benefits and assistance services provider International Medical Group, has also opened an office in Hong Kong, appointing Harry Amende as business development executive.
Malaysian examination glove manufacturer Comfort Glove has reported a profit of M$10.1 million (US$2.4 million) for the first quarter of the year. This is a significant increase on the same period last year when the company was hit by a fire. Quarter-on-quarter, revenues were up 29% to M$93.7 million.
Thanks to listing costs, Hong Kong care home operator Pine Care Group has reported a 54.5% slump in profits for the year to 31 March to HK$12.4 million (US$1.6 million). At the same time, revenues were up 2.6% to HK$177.3 million.
Shares in Sydney-based medical appointment booking service 1st Group jumped 22.2% yesterday after the group announced an agreement with Australian leading health advertising and content provider, Tonic Health Media.
Shares in Australian medtech company Resonance Health rose 3.7% yesterday after Thalassaemia International Federation (TIF), a leading patient organisation in the field of iron overload, endorsed its technology which measures liver iron concentration.
US life science technology company Sanovas has agreed to set up a US$75 million venture capital fund and innovation centre with the People's Government of Suzhou. The centre will be based at the Suzhou Institute of Nanotechnology and NanoBionics (SINANO) at the Chinese Academy of Sciences located within the Suzhou Industrial Park Biotechnology Innovation Centre.


Brisbane-based Oventus has had a good week. First and foremost the sleep disorder device manufacturer has just completed the first tranche of capital raising. It has raised A$6.5 million (US$4.9 million) in a placement of shares at A$0.36 per share. A second tranche to raise A$0.5 million will follow subject to shareholder approval. Bell Potter is managing the deal.
A new report from QBE Insurance, Australia's largest global insurer, reveals that 22% of healthcare companies in Hong Kong have suffered from legal and regulatory compliance issues over the past 12 months. The Risks of Regret report looks at both current and future business challenges and opportunities, and how well-prepared companies are to deal with risks.
“The Asia-Pacific region presents lucrative opportunities for multinational pharmaceutical firms that treat diabetes,” says BMI Research in Singapore in a new report on healthcare in Asia. Fuelled by rapid urbanisation, nutrition transition and increasingly sedentary lifestyles, the epidemic has grown in parallel with the worldwide rise in obesity. Asia’s large population and rapid economic development have made it an epicentre of the epidemic, with India and China the key hotspots in the region, it explains.
Susann Roth, senior social development specialist, Asian Development Bank, explains why the ADB is committed to doubling health sector investments by 2020.
SGX-listed private healthcare provider Health Management International (HMI) has reported an actual loss in profits for the third quarter of the year of M$1.6 million (US$370,000), though stripping out exceptional items, profits were up 12% to M$7.1 million. The loss was predominantly down to one-off fees of M$7.3 million incurred during the group’s M$556.5 million consolidation of its two hospitals in Malaysia, however profits were also eroded by M$1.3 million in forex losses thanks to a weakening ringgit.
Shares in Cayman Islands-incorporated G Medical Innovations, which develops mobile health technologies, declined heavily on their ASX debut yesterday, dropping 30%.
Singapore-listed property developer Perennial Real Estate has reported a 356% rise in profits for the first quarter of the year to S$38.7 million (US$27.5 million) thanks to divestment gains in Singapore. Revenues for the same period slumped 31.5% to S$20.2 million largely due to lower project management fees and lower rental revenue.
First quarter results from Indonesian healthcare companies have been subdued. There is a sense of marking time rather than any major move forward for any of them. Indeed with the exception of Siloam International Hospitals, the country’s largest private hospital operator, the share price of its healthcare rivals are all showing a loss for the year.

The Future of Healthcare in Asia

Round table

Download the round table here

Hedge Fund Focus

HealthInvestor Asia twitter feed
HIA Indices